Salary Range: 290000 to 380000 (Currency: USD) (Pay period: per-year-salary)

Our mission is to develop therapies that empower the immune system to combat neurodegeneration and our team is focused on developing treatments for some of the most challenging diseases facing our society. By harnessing advancements in genetics, immunology and neuroscience, we are pioneering the development of potential therapies to counteract the devastating progression of neurodegeneration. We are supported in this mission by experienced and accomplished scientists and clinicians, a novel portfolio of programs, leading healthcare investors, and pharma company partners, who share in our commitment to bettering the lives of patients and realizing a world where we make brain disorders history.

As Vice President Clinical Development, you will serve as Alector’s senior clinical development physician and a key clinical leader for AL137 as the program enters Phase 1 clinical trials. You will bring your medical judgment, scientific curiosity, and drug development experience to help translate an innovative program into meaningful clinical evidence.

You will provide medical and clinical development leadership across the program, working closely with colleagues in Clinical Operations, Translational Medicine, Regulatory, Safety, Biometrics, and other functions. As the program clinical lead, you will have significant ownership and visibility, helping us make rigorous, patient-centered decisions as AL137 progresses through early clinical development.

This role is designed for a leader and “go-getter” who thrives through influence and hands-on contribution.

Key Goals & Accountabilities

Lead the clinical development strategy for AL137! Own the clinical and medical strategy for Phase 1 and help shape the program's path toward later-stage development, integrating emerging clinical, translational, safety, and biomarker data into clear decisions.

Deliver a high-quality Phase 1 program! Provide medical leadership for protocol design and execution, eligibility and safety considerations, dose escalation, clinical data review, and interpretation of emerging results while partnering closely with Clinical Operations and investigators.

Be Alector's clinical voice! Serve as the internal physician expert for AL137 and provide clear clinical perspectives to program teams and senior leadership. Build productive relationships with investigators, external experts, partners, and regulatory authorities as appropriate.

Turn data into decisions! Partner across Biometrics, Translational Medicine, Safety, Regulatory, and other functions to define evidence needed for critical development decisions and communicate the clinical meaning of emerging data.

Integrate innovative technologies, including AI, into clinical development! Identify practical ways to use AI and emerging technologies to accelerate analysis, improve decision-making, streamline clinical-development work, and conserve valuable time and resources.

Required Qualifications

M.D. (Preferred) or Ph.D. in Neuroscience, Neurobiology, or equivalent field required.

10+ years' experience leading clinical development in the biotechnology or pharmaceutical industry; experience taking programs through early clinical development is essential.
Serving as a subject matter authority (SME): Extensive clinical expertise in the management and execution of Alzheimer Disease (AD) and other related neurodegenerative disease programs.

Drug development experience in neurodegenerative disease.

Strong knowledge of clinical trial design, medical monitoring, clinical data interpretation, benefit-risk assessment, and the regulatory requirements supporting clinical drug development.

Experience designing and executing first-in-human and Phase 1 and 2 studies, including dose escalation and interpretation of early safety, pharmacokinetic, pharmacodynamic, and biomarker data.

Experience working with regulators and contributing clinical content to regulatory submissions and interactions.

Demonstrated ability to exercise independent medical judgment and provide clinical leadership within cross-functional development teams; you are comfortable operating as the primary internal clinical expert for a program.

Ability to translate complex scientific and clinical information into clear recommendations and collaborate effectively with scientists, development colleagues, executives, investigators, and external experts.

You are an active user of large language models (LLMs) and have a strong interest in evolving AI technologies and how they can improve the quality, speed, and efficiency of drug development.

Experience working in a small or rapidly evolving biotechnology organization where clinical leaders combine strategic thinking with hands-on execution.

At Alector, our vision is bold, people are our priority, and our values are at the core of everything we do. Our dynamic and flexible environment encourages our teams to experiment, take ownership of decisions, and question convention to solve complex problems. We value shared wins, perseverance, and a growth mindset, which drives us forward, together.

Among the things you'll discover at Alector from your very first day are our committed and driven colleagues, a bold company vision, and new, modern offices designed to inspire innovation and collaboration in South San Francisco, right at the heart of Biotech Bay. Our benefits are thoughtfully designed around Alectorians and their loved ones and include flexible hybrid work options, competitive compensation, and comprehensive and unique benefits that enhance your health and well-being. Come join us!

We believe that hard-working teams include people from a wide variety of backgrounds and experiences who can challenge each other’s assumptions with fresh perspectives and bring creative ideas to the table. We are committed to building an open, diverse, and inclusive environment for all employees. We do not discriminate on the basis of race, religion, color, national origin, sex, gender, sexual orientation, age, marital status, veteran status, or disability status, or any other characteristics protected under applicable federal, state, or local laws.

We will ensure that individuals with disabilities are provided reasonable accommodation to participate in the job application or interview process, perform essential job functions, and receive other benefits and privileges of employment. Please contact us to request accommodation.

Review our Privacy Policy

About the company

Alector is a biopharmaceutical company that develops therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's. It uses insights from immunology, neurology, and human genetics to create medicines that help the body heal itself. The company focuses on researching and developing novel therapeutic candidates, mainly through early-stage clinical trials to quickly gather disease-specific data and improve the chances of success. Revenue and funding come from partnerships, grants, and eventual product commercialization. Alector aims to advance treatments for unmet medical needs in neurodegenerative diseases by pursuing a pipeline that combines scientific findings with strategic drug development.

Company Size

51-200

Company Stage

IPO

Headquarters

San Francisco, California

Founded

2013

Get referred to Alector

See people who can refer or advise you

Simplify's Take

What believers are saying

Alector held $172.8 million cash on June 30, 2026, funding operations through 2027.
AL137 cleared IND-enabling studies, with IND submission targeted for Q1 2027.
AL050 and AL064/AL164 advanced in 2026, broadening shots on goal beyond Alzheimer’s.

What critics are saying

GSK ends its collaboration on January 2, 2027, crushing Alector's partner-funded model.
Latozinemab, nivisnebart, and AL002 all failed, exposing weak clinical translation across programs.
If AL137 misses IND or early efficacy, Alector becomes a preclinical platform with no anchor asset.

What makes Alector unique

Alector's ABC platform targets blood-brain barrier delivery across antibodies, enzymes, and siRNA.
It pairs neuroimmunology with human genetics, concentrating on genetically validated neurodegeneration targets.
The company runs lean through outsourcing, preserving capital for a small internal team.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours
Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

2 year growth

MarketScreener

Oct 16th, 2026

Alector prices $75M stock offering at $2.05 per share, a 7.3% premium

Alector, a South San Francisco biotechnology company developing therapies for neurodegeneration, has priced an underwritten offering of 36,600,000 common shares at $2.05 each. The price is about 7.3% above the October 15, 2026 closing price. Gross proceeds are expected to reach $75,030,000 before fees and expenses. Investors include TCGX, BVF Partners, ADAR1 Capital Management, and Deep Track Capital. Alector plans to use the money for general corporate purposes, including research, development, manufacturing, working capital, and possible acquisitions. Morgan Stanley & Co. LLC and BTIG, LLC are joint lead book-running managers. The offering is expected to close on or about October 19, 2026, subject to customary closing conditions.

Defense World

Oct 6th, 2026

Penny stocks to watch now - october 5th.

Penny stocks to watch now - october 5th. HeartBeam, Alector, Inspira Technologies OXY B.H.N., Inspira Technologies OXY B.H.N., and Alpha Modus are the five Penny stocks to watch today, according to MarketBeat's stock screener tool. Penny stocks are shares of very small or early-stage companies that trade at a low price, often below $5 per share, and may be listed on major exchanges or over-the-counter markets. They typically have lower trading volume, less publicly available information, and greater price volatility and risk than established stocks. These companies had the highest dollar trading volume of any Penny stocks within the last several days. HeartBeam (BEAT). BioTelemetry, Inc., a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. Discover more Military aircraft engines Track Defense News Join the Air Force Alector (ALEC). Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. Inspira Technologies OXY B.H.N. (QTEX). Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation (MV) for the treatment of respiratory failure. Its lead product is the augmented respiration technology system (ART), a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. Inspira Technologies OXY B.H.N. (IINN). Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. Alpha Modus (AMOD). Alpha Modus Holdings, Inc. operates as a blank check company. The company was founded on December 13, 2024 and is headquartered in Cornelius, NC.

GlobeNewswire

Oct 5th, 2026

Alector enters global license agreement with Genentech for brain penetrant GCase Enzyme Replacement Therapy for Parkinson's Disease and other neurodegenerative diseases.

Alector enters global license agreement with Genentech for brain penetrant GCase Enzyme Replacement Therapy for Parkinson's Disease and other neurodegenerative diseases. October 05, 2026 07:00 ET | Source: Alector, Inc. Alector grants Genentech exclusive rights to develop and commercialize AL050, an investigational GCase Enzyme Replacement Therapy (ERT) enabled by Alector Brain Carrier (ABC), Alector's proprietary blood-brain barrier delivery platform Alector to receive $100 million upfront payment, with potential for up to $1.17 billion in additional milestone payments, as well as tiered royalties on net sales SOUTH SAN FRANCISCO, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) - Alector, Inc. (Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced it has entered into an exclusive global licensing agreement with Genentech, a member of the Roche Group, granting Genentech worldwide rights to develop and commercialize Alector's AL050 program, its brain-penetrant engineered glucocerebrosidase (GCase) ERT. AL050 is designed to address GCase deficiency, a driver of neurodegeneration in Parkinson's Disease that is most pronounced in - but not limited to - carriers of GBA1 mutations. It combines an Alector-engineered GCase, optimized for greater enzymatic activity and a longer half-life, with Alector's ABC, which is designed to transport therapeutics across the blood-brain barrier. Delivered into the brain, the enzyme is intended to break down glucosylsphingosine and glucosylceramide, lipids that accumulate in neurons and other brain cells upon GCase deficiency and contribute to neurodegeneration, with the aim of reducing cellular dysfunction and slowing disease progression. "Deficient GCase activity is increasingly recognized as a contributor to Parkinson's Disease, and there is still no approved therapy that addresses the underlying enzyme deficiency," said Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector. "The challenge in treating GCase deficiency is twofold: engineering an enzyme with optimal activity and durability and successfully delivering it to the brain. AL050 addresses this by pairing an engineered GCase enzyme with our proprietary Alector Brain Carrier technology designed to cross the blood-brain barrier. Genentech's long-standing commitment to Parkinson's Disease makes them an ideal partner as this program moves toward the clinic". "Parkinson's Disease is one of the fastest-growing neurological conditions worldwide," said Boris L. Zaïtra, Head of Roche Corporate Business Development. "By partnering with companies such as Alector we aim to delay or halt the progression of Parkinson's so patients maintain and prolong their independence." Under the terms of the agreement, Alector will receive an upfront payment of $100 million and is also eligible to receive additional payments of up to $1.17 billion upon the achievement of development, regulatory, and commercial milestones. Alector is also eligible for tiered royalties on net sales. Under the collaboration, Genentech will be responsible for development, regulatory, manufacturing, and commercialization across all indications. Alector retains ownership of ABC and full rights to apply the platform across its wholly owned pipeline. "This partnership extends our cash runway into 2029, providing resources to advance our fully active, subcutaneously delivered, brain-enabled anti-Aβ antibody to multi-cohort clinical data in Alzheimer's patients, and move our subcutaneously delivered, brain-enabled Tau siRNA and alpha- synuclein siRNA programs through IND-enabling studies and to IND filings," said Dr. Rosenthal. Alector R&D Webinar on Wholly Owned Pipeline Alector will host a scientific webinar on Tuesday, October 13th, 2026, at 8:00 a.m. PT, focused on AL137, its brain-enabled anti-Aβ antibody; AL164, its tau siRNA program; and AL062, its alpha-synuclein siRNA program. Registration and webcast information will be available on the Events and Presentations page of the Alector corporate website. About Alector Alector is a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of programs that aim to remove toxic proteins, replace missing proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector's product candidates seek to treat a range of indications, such as Alzheimer's disease and Parkinson's disease. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being applied to its preclinical and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper brain penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California. For more information, please visit www.alector.com. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements regarding our business plans, business strategy, product candidates, research and preclinical pipeline, blood-brain barrier technology platform, planned and ongoing preclinical studies, planned clinical trials, expected milestones, expectations of our collaborations, and financial and cash guidance. Such statements are subject to numerous risks and uncertainties, including but not limited to risks and uncertainties as set forth in Alector's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, with the Securities and Exchange Commission (SEC), as well as the other documents Alector files from time to time with the SEC. These documents contain and identify important factors that could cause the actual results for Alector to differ materially from those contained in Alector's forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and Alector specifically disclaims any obligation to update any forward-looking statement, except as required by law. Alector Contacts Argot Partners (media) David Rosen 646-461-6387 [email protected] Argot Partners (investors) Laura Perry [email protected]

MarketBeat

Aug 6th, 2026

Alector (NASDAQ:ALEC) releases earnings results, beats expectations by $0.02 EPS.

Alector (NASDAQ:ALEC) releases earnings results, beats expectations by $0.02 EPS. August 6, 2026 Key points. * Alector beat quarterly expectations: The biotechnology company reported a loss of $0.21 per share, $0.02 better than analysts' forecast, while revenue of $3.32 million exceeded the $1.43 million consensus estimate. * Shares rose amid heavy trading: Alector stock gained $0.34 to $1.83, with trading volume far above average. Despite strong liquidity, the company remained deeply unprofitable, posting a negative net margin of 680.83%. * Analyst sentiment remains mixed: Alector has an average "Hold" rating and a $3.62 price target, while recent recommendations ranged from "Sell" and "Underweight" to "Overweight." Company insiders sold 115,760 shares over the past 90 days. * MarketBeat previews the top five stocks to own by September 1st. Alector (NASDAQ:ALEC - Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.21) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.02, FiscalAI reports. The business had revenue of $3.32 million for the quarter, compared to the consensus estimate of $1.43 million. Alector had a negative net margin of 680.83% and a negative return on equity of 295.17%. Alector stock performance. Alector stock traded up $0.34 during midday trading on Thursday, reaching $1.83. 5,702,966 shares of the company's stock were exchanged, compared to its average volume of 484,769. The stock's 50-day simple moving average is $1.69 and its 200 day simple moving average is $2.01. The firm has a market cap of $203.18 million, a price-to-earnings ratio of -1.54 and a beta of 0.60. The company has a debt-to-equity ratio of 0.80, a quick ratio of 5.25 and a current ratio of 5.25. Alector has a 52 week low of $1.09 and a 52 week high of $3.40. Analyst Ratings changes. Several research firms have weighed in on ALEC. Morgan Stanley reiterated an "underweight" rating and set a $2.00 target price on shares of Alector in a report on Monday, May 4th. Wall Street Zen upgraded shares of Alector from a "sell" rating to a "hold" rating in a report on Saturday, May 9th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Alector in a report on Friday, July 31st. Finally, Cantor Fitzgerald upgraded shares of Alector from a "neutral" rating to an "overweight" rating in a report on Wednesday, April 15th. Three investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Alector currently has an average rating of "Hold" and an average price target of $3.62. Discover more Business News Stock Profit Calculator MarketBeat Research Tools Insider buying and selling. In other news, CEO Arnon Rosenthal sold 87,216 shares of the business's stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $1.97, for a total transaction of $171,815.52. Following the completion of the sale, the chief executive officer owned 2,367,206 shares in the company, valued at $4,663,395.82. The trade was a 3.55% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Neil Lindsay Berkley sold 19,360 shares of the company's stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $1.97, for a total value of $38,139.20. Following the completion of the transaction, the chief financial officer directly owned 379,900 shares in the company, valued at approximately $748,403. This represents a 4.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 115,760 shares of company stock valued at $227,734. Insiders own 8.30% of the company's stock. Institutional inflows and outflows. A number of institutional investors and hedge funds have recently made changes to their positions in the business. Jane Street Group LLC grew its position in Alector by 4.7% during the first quarter. Jane Street Group LLC now owns 256,551 shares of the company's stock worth $316,000 after buying an additional 11,618 shares in the last quarter. Strs Ohio bought a new stake in shares of Alector during the 1st quarter valued at approximately $126,000. Geode Capital Management LLC increased its holdings in shares of Alector by 1.0% during the second quarter. Geode Capital Management LLC now owns 1,982,068 shares of the company's stock worth $2,775,000 after buying an additional 19,970 shares in the last quarter. Prudential Financial Inc. acquired a new stake in shares of Alector during the second quarter valued at about $30,000. Finally, XTX Topco Ltd boosted its position in Alector by 125.2% during the 2nd quarter. XTX Topco Ltd now owns 73,338 shares of the company's stock worth $103,000 after buying an additional 40,767 shares during the period. Institutional investors and hedge funds own 85.83% of the company's stock. About Alector. Alector is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector's approach aims to harness the body's natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer's disease and frontotemporal dementia. The company's pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer's disease studies. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Alector, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alector wasn't on the list. While Alector currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Yahoo Finance

May 8th, 2026

Alector reports Q1 loss of $0.21 per share, misses revenue estimates by 65%

Alector reported a first-quarter loss of $0.21 per share, beating the consensus estimate of a $0.35 loss by 40%. This marks the fourth consecutive quarter the biotechnology company has surpassed earnings expectations. The result improved from a loss of $0.41 per share in the same period last year. However, the company missed revenue targets, posting $1.05 million against expectations of $3 million, a 65.13% shortfall. This compares to revenue of $3.67 million in the year-ago quarter. Alector shares have gained 64.7% year-to-date, outperforming the S&P 500's 7.6% gain. Despite the earnings beat, unfavourable estimate revisions have resulted in a Zacks Rank of four, suggesting potential near-term underperformance.

Alector

Vice President Clinical Development

About the job